EBS Emergent BioSolutions Inc.

EMERGENT 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Emergent BioSolutions, Inc. – EBS

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE: EBS). Investor losses must relate to purchases of the Company’s common stock between January 11, 2016 and June 21, 2016. This action is pending in the United States District Court for the District of Maryland.

What You May Do

If you purchased shares of Emergent and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by September 19, 2016.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
17/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Receives New Contract Modification for ACAM2000®...

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancil...

 PRESS RELEASE

Emergent BioSolutions Awarded $30 Million Contract Modification for CY...

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed...

 PRESS RELEASE

Emergent BioSolutions Underscores Continued Support of Increasing Nalo...

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's “Campus Surge” initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of Inter...

 PRESS RELEASE

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Wells Fargo 20th Annual Healthcare ConferenceSeptember 4, 20253:00 pm ETWebcast link One-on-one meetings HCW 27th Annual Global Investment ConferenceSeptember 9, 20251:30 PM ETWebcast link One-on-one meetings Please contact your conference representative to request one-on-one meetings. Participa...

 PRESS RELEASE

Emergent BioSolutions Supports Voices for Awareness and Facing Fentany...

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™ GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch